Published Date: 16 Mar 2023
The FDA has approved tropinetide (Daybue; Acadia Pharmaceuticals) to treat Rett syndrome in patients 2 years of age and older.
Read Full NewsQurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes
1.
Do Anatomy Atlases Reflect Social Inequalities?
2.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
3.
Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer
4.
Charles III, King of Kings, is Cancerous.
5.
Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.
1.
Unlocking a New Era in Bladder Cancer Treatment: A Review of the TAR-200 Intravesical Drug Delivery System
2.
Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways
3.
Precision Erythropoietic Modeling for Hematologic Disorders
4.
A Clinical Review of Novel Therapeutics for Rare Cancers in the Genomics Era
5.
Medical Education Through Multidisciplinary Learning Models for Complex Cancer Care
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
5.
Understanding Platelet Disorders
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation